Income Statement
MONTE ROSA THERAPEUTICS, INC.
GLUE
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
177.88 | 156.73 | 143.31 | 112.38 | 72.88 |
|
Research & Development
|
141.50 | 121.56 | 111.27 | 85.06 | 57.16 |
|
Selling, General & Administrative
|
36.38 | 35.17 | 32.04 | 27.32 | 15.73 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-177.88 | -156.73 | -143.31 | -112.38 | -72.88 |
|
Non-Operating Income
|
14.49 | 10.98 | 8.30 | 3.88 | -1.08 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-39.72 | -70.13 | -135.01 | - | - |
|
Income Tax Expense
|
-1.10 | 2.57 | 0.34 | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-38.63 | -72.70 | -135.35 | -108.50 | -73.96 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-177.88 | -156.73 | -143.31 | -112.38 | -72.88 |
|
Earnings Per Share (Basic)
|
- | - | - | - | - |
|
Diluted EPS
|
- | - | - | - | - |
|
Weighted Average Shares
|
83.07 | 73.91 | 51.40 | 47.23 | - |
|
Diluted Weighted Avg Shares
|
83.07 | 73.91 | 51.40 | 47.23 | - |
|
Comprehensive Income
|
-39.10 | -73.33 | -136.32 | -108.23 | -74.92 |